Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018)

Neogenomics' (NEO) quarterly Non-Current Deffered Revenue came in at $1.2 million in Q3 2018, up 85.03% on a QoQ basis from $648000.0 in Q2 2018.

Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends

Neogenomics (NEO) has 2 years of Non-Current Deffered Revenue data on file, last reported at $1.2 million in Q3 2018.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $1.2 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $1.2 million (changed N/A YoY) and the FY2017 annual result came in at $283000.0, changed N/A from the prior year.
Non-Current Deffered Revenue improved to $1.2 million in Q3 2018, from $648000.0 in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $1.2 million in Q3 2018 to a low of $283000.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn	-
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn	-
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn	32.59 Mn
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn	-
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn	-
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn	17.00 Mn
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn	-
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn	-
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn	-
10	Neogenomics	2.05 Bn	1.90 Bn	91.88 Mn	-

Download Data